•
Dec 31, 2019

IFF Q4 2019 Earnings Report

IFF reported a 5% increase in sales and an EPS of $0.70 for the fourth quarter of 2019.

Key Takeaways

IFF reported a 5% increase in net sales to $1.28 billion for the fourth quarter of 2019. Reported EPS was $0.70, while adjusted EPS ex amortization was $1.46. The company continued to achieve significant cost synergies from Frutarom and captured solid year one revenue synergies.

Delivered high-single digit currency neutral top-line growth.

Achieved a robust double-digit increase in adjusted EPS ex amortization.

Continued to achieve significant cost synergies from Frutarom well ahead of year-one targets.

Captured solid year one revenue synergies, demonstrating broad operational strength.

Total Revenue
$1.28B
Previous year: $1.22B
+5.3%
EPS
$1.46
Previous year: $1.22
+19.7%
Operating Margin
9%
Free Cash Flow
$699M
Gross Profit
$502M
Previous year: $478M
+5.2%
Cash and Equivalents
$624M
Previous year: $635M
-1.7%
Free Cash Flow
$240M
Previous year: $168M
+43.1%
Total Assets
$13.3B
Previous year: $12.9B
+3.5%

IFF

IFF

IFF Revenue by Segment

Forward Guidance

The Company's 2020 guidance is as follows: Sales $5.15B - $5.35B, Adjusted EPS $4.89 - $5.14 and Adjusted EPS Ex Amortization $6.20 - $6.45.

Positive Outlook

  • Sales growth for 2020 is expected to be approximately 1% to 5% on a currency neutral basis.
  • Excluding the impacts of the 53rd week in the prior year period and an anticipated 0.5 percentage point impact, principally related to the carryover effect from the Russia/Ukraine compliance issue and CitraSource, currency neutral core sales growth is expected to be approximately 2.5% to 6.5%.
  • Adjusted EPS ex amortization growth for 2020 is expected to be approximately 3.5% to 7.5% on a currency neutral basis.
  • Offsetting the negative impacts is a 6 percentage point contribution from integration synergies.
  • The Company expects to achieve a Net Debt to EBITDA ratio of less than 3.0x by the end of 2020.

Challenges Ahead

  • Currency is expected to negatively impact sales by an estimated 1 percentage point, and adjusted EPS ex amortization by 3 percentage points.
  • Sales growth for 2020 includes an estimated 1 percentage point impact related to the 53rd week in the prior year period and an anticipated 0.5 percentage point impact, principally related to the carryover effect from the Russia/Ukraine compliance issue and CitraSource.
  • Adjusted EPS ex amortization growth for 2020 includes an estimated 5 percentage point impact related to an incentive compensation reset, an estimated 1 percentage point impact related to the 53rd week in the prior year period and an anticipated 0.5 percentage point impact, principally related to the carryover effect from the Russia/Ukraine compliance issue and CitraSource.
  • The Company expects a modest impact from the recent coronavirus outbreak in Asia, based on its knowledge at this time.
  • There are still too many variables and uncertainties regarding this outbreak to quantify currently.

Revenue & Expenses

Visualization of income flow from segment revenue to net income